Search clinical trials for: MT-6548-matching placebo

Total 1116 results

Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety Study to Evaluate MT-6548 in Hemodialysis Subjects Currently Receiving ESAs With Anemia Associated With Chronic Kidney Disease in Japan

Anemia; Hemodialysis Dependent Chronic Kidney Disease

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety Study to Evaluate MT-6548 in Hemodialysis Subjects Not Receiving ESAs With Anemia Associated With Chronic Kidney Disease in Japan

Anemia; Hemodialysis Dependent Chronic Kidney Disease

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety Study to Evaluate MT-6548 in Peritoneal Dialysis Subjects With Anemia Associated With Chronic Kidney Disease in Japan

Anemia; Peritoneal Dialysis Dependent Chronic Kidney Disease

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety Study to Evaluate MT-6548 in Non-dialysis Subjects With Anemia Associated With Chronic Kidney Disease in Japan

Anemia; Non-dialysis Dependent Chronic Kidney Disease

Japan
The University of Texas Health Science Center,...
United States Department of Defense; Akebia Therapeutics Inc.

Completed

Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19)

Coronavirus Infection | Acute Respiratory Distress Syndrome

United States
Akebia Therapeutics

Completed

Dose-Finding Study of Vadadustat in Japanese Subjects With Anemia Secondary to Dialysis-Dependent Chronic Kidney Disease (DD-CKD)

Anemia | Dialysis Dependent Chronic Kidney Disease

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Effects of Iron Supplements on the Pharmacokinetics of MT-6548

Healthy

Japan
Akebia Therapeutics

Completed

Dose-Finding Study of Vadadustat in Japanese Subjects With Anemia Secondary to Non-Dialysis Dependent Chronic Kidney Disease (NDD-CKD)

Anemia | Non-dialysis Dependent Chronic Kidney Disease

Japan
Mitsubishi Tanabe Pharma America Inc.

Terminated

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of MT-6345 in Healthy Subjects

Healthy

United Kingdom
Mitsubishi Tanabe Pharma America Inc.

Completed

MT-8554 for Reduction of Vasomotor Symptoms in Postmenopausal Women

Menopause Hot Flashes

United States
Mitsubishi Tanabe Pharma Corporation

Completed

Dose-finding Study of MT-1303

Relapsing-remitting Multiple Sclerosis

Croatia, Bulgaria, Czech Republic, Italy, Russian Federation, Spain, United Kingdom, Germany, Lithuania, Poland, Belgium, Hungary, Serbia, Finland, Ukraine, Switzerland, Canada, Turkey
Mitsubishi Tanabe Pharma Corporation

Completed

Dose-finding Study of MT-1303 in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Plaque Psoriasis

Bulgaria, Russian Federation, Estonia, Hungary, Latvia, Poland, Ukraine, Germany
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety of MT-3995 in Patients With Diabetic Nephropathy

Diabetic Nephropathy

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Safety, Tolerability and Pharmacokinetic Study of MT-3995 in Subjects With Diabetic Nephropathy

Diabetic Nephropathy

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of MT-8554 in Female Subjects Experiencing Vasomotor Symptoms

Vasomotor Symptoms

Germany
Mitsubishi Tanabe Pharma Corporation

Completed

Study to Assess the Efficacy, Safety and Tolerability of MT- 8554 in Subjects With Painful Diabetic Peripheral Neuropathy

Painful Diabetic Peripheral Neuropathy

Germany, Hungary, Poland
Akebia Therapeutics

Completed

42-Day Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and Anemia

Anemia | Kidney Disease

United States
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety of MT-3995 in Patients With Non-Alcoholic Steatohepatitis(NASH)

NASH

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of MT-7117 in Healthy Subjects

Healthy

United Kingdom
Mitsubishi Tanabe Pharma Corporation

Completed

A Clinical Study to See How the Study Drug MT-4129 is Taken up by the Body in Healthy Volunteers

Healthy

Netherlands
Mitsubishi Tanabe Pharma Corporation

Completed

Safety, Tolerability and Pharmacokinetic Study of MT-3995 at a Low Dose in Subjects With Diabetic Nephropathy

Diabetic Nephropathy

Japan
Mitsubishi Tanabe Pharma America Inc.

Completed

Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria

Erythropoietic Protoporphyria (EPP)

United States
Bausch Health Americas, Inc.

Active, not recruiting

Study Evaluating Efficacy and Safety of Amiselimod (MT-1303) in Mild to Moderate Ulcerative Colitis

Ulcerative Colitis

United States
Mitsubishi Tanabe Pharma America Inc.

Completed

Definitive QT Study With MT-8554 (MT-8554 DQT)

Healthy Volunteer

United Kingdom
Mitsubishi Tanabe Pharma Corporation

Completed

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of MT-8554 in Healthy Subjects

Healthy

United Kingdom
Mitsubishi Tanabe Pharma America Inc.

Completed

Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria or X-Linked Protoporphyria

EPP | XLP

Spain, United States, Germany, Norway, Italy, Australia, Canada, Japan, Sweden, United Kingdom
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety of MT-5199 in Subjects With Tardive Dyskinesia

Tardive Dyskinesia

Japan
Mitsubishi Tanabe Pharma America Inc.

Completed

Safety and Efficacy Study of MT-2990 in Women With Endometriosis

Endometrial Related Pain

United States
Senju Pharmaceutical Co., Ltd.
PPD

Terminated

A Study to Assess the Safety, Tolerability and Effectiveness of MT-0814 for the Treatment of Age-related Macular Degeneration

Age-related Macular Degeneration

United States
Mitsubishi Tanabe Pharma Corporation

Completed

A Clinical Study to Investigate How Safe and Tolerable the Study Drug MT-2990 is and How MT-2990 is Taken up by the Body in Healthy Volunteers

Healthy

Netherlands
Mitsubishi Tanabe Pharma Corporation

Completed

Safety and Efficacy of MT-1303 in Subjects With Moderate to Severe Active Crohn's Disease

Crohn's Disease

France, Israel, Italy, Netherlands, Poland, Slovakia, Ukraine, Czech Republic, Germany, Hungary, Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety of MT-5547 in Patients With Osteoarthritis Accompanied by Moderate to Severe Pain

Osteoarthritis, Knee / Osteoarthritis, Hip

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Safety and Immunogenicity of MT-5625 in Healthy Adults, Toddlers and Infants

Healthy

Australia, South Africa
Mitsubishi Tanabe Pharma Corporation

Completed

A Study to Evaluate Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of MT-3995 in Type II Diabetic Nephropathy Subjects With Albuminuria

Diabetic Nephropathy

Lithuania, Romania, Bulgaria, Hungary, Slovakia
Nowarta Biopharma Inc

Completed

A Phase I/II Double-blind Safety and Efficacy Evaluation of Nowarta110 in Patients With Plantar Warts

Plantar Warts

United States
Mitsubishi Tanabe Pharma Corporation

Completed

Study of Oral Edaravone in Healthy Adult Males

Healthy Adult Subjects

Japan
Mitsubishi Tanabe Pharma America Inc.

Completed

Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Diffuse Cutaneous Systemic Sclerosis

Diffuse Cutaneous Systemic Sclerosis

Spain, Belgium, United States, United Kingdom, Poland, Canada, Germany, Italy
Mitsubishi Tanabe Pharma Corporation

Completed

A Study to Evaluate Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of MT-3995 in Type II Diabetic Nephropathy Subjects With Albuminuria and Moderately Decreased GFR

Diabetic Nephropathy

Romania, Bulgaria, Hungary, Poland, Czech Republic, Slovakia
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of the Efficacy and Tolerability of Pancrelipase Microtablet (MT) Capsules for the Treatment of Cystic Fibrosis-dependent Exocrine Pancreatic Insufficiency

Malabsorption Syndromes | Cystic Fibrosis | Steatorrhea | Exocrine Pancreatic Insufficiency

United States, Canada
Mitsubishi Tanabe Pharma Corporation

Recruiting

A Study of MT-0551 in Patients With Systemic Sclerosis

Systemic Sclerosis

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Exploratory Study of MT-8554 in Subjects With Painful Diabetic Peripheral Neuropathy

Painful Diabetic Peripheral Neuropathy

Japan
Medicago
Mitsubishi Tanabe Pharma Corporation

Terminated

Safety Immunogenicity Study of MT-2766 in Japanese Adults（COVID-19）

SARS-CoV-2 Infection

Japan
Mayo Clinic
National Heart, Lung, and Blood Institute (NHLBI); Remastered Sleep LLC

Recruiting

Novel Myofunctional Water Bottle to Reduce OSA and Snoring Study

Snoring | Obstructive Sleep Apnea

United States
Resverlogix Corp

Not yet recruiting

A Two-Part Phase 2a Study of RVX000222 in Patients With End-Stage Renal Disease Treated With Hemodialysis

Kidney Failure, Chronic
Huabo Biopharm Co., Ltd.

Completed

A Study of HB0017 in Patients With Moderate to Severe Plaque Psoriasis

Plaque Psoriasis

China
Syneos Health
Shanghai Novamab Biopharmaceuticals Co. Ltd.

Terminated

First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036

Asthma

Australia
GlaxoSmithKline

Recruiting

Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA) (OCEAN)

Eosinophilic Granulomatosis With Polyangiitis

Canada, France, Italy, Spain, Belgium, Korea, Republic of, United States, Japan, China, Czechia, Hungary, Israel, Portugal, Poland, Netherlands, United Kingdom, Austria, Argentina, Australia, Brazil, Germany, Sweden
Toray Industries, Inc

Terminated

Efficacy and Safety of MT-9938 for Treatment of Uremic Pruritus in Subjects With End-stage Renal Disease Receiving Hemodialysis

Uremic Pruritus

United States
Akebia Therapeutics

Completed

20-Week Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and Anemia

Anemia | Chronic Kidney Disease

United States
Takeda

Completed

Phase 1, TAK-648, Single-Rising Dose Study

Healthy Volunteers

Search clinical trials for: MT-6548-matching placebo

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Armenia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations